These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 904743)
1. VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors. Mechl Z; Rovný F; Sopková B Neoplasma; 1977; 24(4):411-4. PubMed ID: 904743 [TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours. Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645 [TBL] [Abstract][Full Text] [Related]
3. EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma. Schulman CC; Rozencweig M; Staquet M; Kenis Y; Sylvester R Eur Urol; 1976; 2(6):271-3. PubMed ID: 829223 [TBL] [Abstract][Full Text] [Related]
4. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)]. Jankowski RP; Vahrson H Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083 [TBL] [Abstract][Full Text] [Related]
5. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract]. Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215 [No Abstract] [Full Text] [Related]
6. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26. Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234 [No Abstract] [Full Text] [Related]
7. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell. Allen LM Cancer Res; 1978 Aug; 38(8):2549-54. PubMed ID: 667850 [No Abstract] [Full Text] [Related]
8. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma. Rodriguez LH; Johnson DE; Holoye PY; Samuels ML Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624 [No Abstract] [Full Text] [Related]
9. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study. Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547 [No Abstract] [Full Text] [Related]
10. [New antineoplastic drugs of the podophyllotoxin derivative group]. Robak T; Płuzańska A Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283 [No Abstract] [Full Text] [Related]
11. 4'-Demethylepipodophyllotoxin-beta-D-glucoside: a new podophyllotoxin derivative with VM-26-like and VP-16-213-like activities. Gupta RS; Singh B J Natl Cancer Inst; 1984 Jul; 73(1):241-8. PubMed ID: 6588229 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. Schulman C; Sylvester R; Robinson M; Smith P; Lachand A; Denis L; Pavone-Macaluso M; De Pauw M; Staquet M Recent Results Cancer Res; 1978; 68():338-45. PubMed ID: 111322 [TBL] [Abstract][Full Text] [Related]
13. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma. Rivera G; Green A; Hayes A; Avery T; Pratt C Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594 [TBL] [Abstract][Full Text] [Related]
14. 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review. Goldsmith MA; Carter SK Eur J Cancer (1965); 1973 Jul; 9(7):477-82. PubMed ID: 4609765 [No Abstract] [Full Text] [Related]
15. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Loike JD; Brewer CF; Sternlicht H; Gensler WJ; Horwitz SB Cancer Res; 1978 Sep; 38(9):2688-93. PubMed ID: 679171 [TBL] [Abstract][Full Text] [Related]
16. A quantitative microdensitometric and autoradiographic study of the effect of 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26) on the cell cycle of cultured fibroblasts. Gotzos V; Cappelli-Gotzos B; Despond JM Histochem J; 1979 Nov; 11(6):691-707. PubMed ID: 536243 [TBL] [Abstract][Full Text] [Related]
17. [Surgically treated supratentorial gliomas in the adult. Favourable action of a podophyllin derivative (VM 26) administered alone (author's transl)]. Trouillas P; Chassard JL; Tommasi M; Aimard G; Devic M Nouv Presse Med; 1978 Dec; 7(44):4017-9. PubMed ID: 733569 [TBL] [Abstract][Full Text] [Related]
18. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study. Eur Urol; 1976; 2(3):138-41. PubMed ID: 70352 [TBL] [Abstract][Full Text] [Related]
19. Uridine enhances the chemotherapeutic action of the 4'-demethylepipodophyllotoxin-thenylidene-glucoside (VM 26)-cyclophosphamide combination on i.m. implanted Ehrlich carcinoma. Osswald H Arzneimittelforschung; 1978; 28(3):387-8. PubMed ID: 580745 [TBL] [Abstract][Full Text] [Related]
20. Nonresponsiveness of brain tumors to VM-26 therapy in children. Sullivan MP; van Eys J; Herson J; Starling KA; Ragab A; Sexhauer C Cancer Treat Rep; 1979 Jan; 63(1):155-6. PubMed ID: 369689 [No Abstract] [Full Text] [Related] [Next] [New Search]